Trial · NCT04798781

Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma

NCT04798781, Phase 2, Completed, Andrew Hendifar, MD; results first posted 2024-10-10

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma. Trials, record NCT04798781. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04798781

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma
NCT number: NCT04798781
Status: Completed
Phases: Phase 2
Enrollment: 16 participants, actual
Lead sponsor: Andrew Hendifar, MD
Conditions: Gastric Cancer, Hepatocellular Carcinoma
Interventions: Telatinib, Keytruda
First posted: 2021-03-15
Last updated: 2025-12-11
Results first posted: 2024-10-10

Source ClinicalTrials.gov

Registered outcomes5

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Progression-free Survival	through study completion, approximately 2.5 years	Duration of time from start of treatment until progression or death, whichever comes first
Secondary	Overall Response Rate	from the start of treatment until the end of treatment, approximately 12 months	The percentage of patients who have a partial or complete response to treatment
Secondary	Disease Control Rate	from the start of treatment until the end of treatment, approximately 12 months	The percentage of patients who have stable disease, partial response, or complete response to treatment
Secondary	Overall Survival	from the start of treatment until time-of-event	The length of time from the start of treatment that patients are still alive
Secondary	Number and Severity of Adverse Events	from the start of treatment until 30 days following the end of treatment or until initiation of a new anticancer therapy (whichever occurs first), approximately 13 months	Incidence and severity of adverse events as measured by the National Cancer Institute Common Terminology Criteria for Adverse Events Version 5

Source ClinicalTrials.gov

Outcomes5

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Progression-free Survival	through study completion, approximately 2.5 years	Days	MEAN
SECONDARY	Overall Response Rate	from the start of treatment until the end of treatment, approximately 12 months	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Disease Control Rate	from the start of treatment until the end of treatment, approximately 12 months	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Overall Survival	from the start of treatment until time-of-event	days	MEDIAN
SECONDARY	Number and Severity of Adverse Events	from the start of treatment until 30 days following the end of treatment or until initiation of a new anticancer therapy (whichever occurs first), approximately 13 months	Adverse Events (AEs)	COUNT_OF_UNITS

Source ClinicalTrials.gov

Results by group9

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Progression-free Survival	telatinib + Keytruda		153.87	Standard Deviation 133.69	Days
Overall Response Rate	telatinib + Keytruda		0		Participants
Disease Control Rate	telatinib + Keytruda		8		Participants
Overall Survival	telatinib + Keytruda		258	95% Confidence Interval 116 to 1238	days
Number and Severity of Adverse Events	telatinib + Keytruda	Grade 1	161		Adverse Events (AEs)
Number and Severity of Adverse Events	telatinib + Keytruda	Grade 2	87		Adverse Events (AEs)
Number and Severity of Adverse Events	telatinib + Keytruda	Grade 3	57		Adverse Events (AEs)
Number and Severity of Adverse Events	telatinib + Keytruda	Grade 4	7		Adverse Events (AEs)
Number and Severity of Adverse Events	telatinib + Keytruda	Grade 5	1		Adverse Events (AEs)

Source ClinicalTrials.gov

Participant flow3

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	telatinib + Keytruda	16
Overall Study	COMPLETED	telatinib + Keytruda	15
Overall Study	NOT COMPLETED	telatinib + Keytruda	1

Source ClinicalTrials.gov

Adverse events110

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Abdominal pain	Gastrointestinal disorders	telatinib + Keytruda	3	16	5
other	Alanine Aminotransferase	Investigations	telatinib + Keytruda	5	16	16
other	Alkaline Phosphatase Increased	Investigations	telatinib + Keytruda	1	16	5
other	Allergic Rhinitis	Respiratory, thoracic and mediastinal disorders	telatinib + Keytruda	1	16	1
other	Alopecia	Skin and subcutaneous tissue disorders	telatinib + Keytruda	1	16	1
other	Anal Fistula	Gastrointestinal disorders	telatinib + Keytruda	1	16	1
other	Anemia	Blood and lymphatic system disorders	telatinib + Keytruda	5	16	17
other	Anorexia	Metabolism and nutrition disorders	telatinib + Keytruda	3	16	4
other	Anxiety	Psychiatric disorders	telatinib + Keytruda	2	16	2
other	Arthralgia	Musculoskeletal and connective tissue disorders	telatinib + Keytruda	2	16	4

1 to 10 of 110Source ClinicalTrials.gov

See all 110 adverse events

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	telatinib + Keytruda	12	16
Total, other adverse events	telatinib + Keytruda	16	16
Total, serious adverse events	telatinib + Keytruda	8	16

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT04798781

GET https://conductscience.org/api/trials/v1/NCT04798781/events?page=2

API reference For AI assistants